MD MBA - Finch Therapeutics Chief Officer
| FNCHDelisted Stock | USD 8.51 0.19 2.18% |
Insider
MD MBA is Chief Officer of Finch Therapeutics Group
| Phone | 617 229 6499 |
| Web | https://www.finchtherapeutics.com |
Finch Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2194) % which means that it has lost $0.2194 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6264) %, meaning that it created substantial loss on money invested by shareholders. Finch Therapeutics' management efficiency ratios could be used to measure how well Finch Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Finch Therapeutics Group currently holds 30.13 M in liabilities with Debt to Equity (D/E) ratio of 0.35, which is about average as compared to similar companies. Finch Therapeutics has a current ratio of 7.13, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Finch Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Finch Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Finch Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Finch to invest in growth at high rates of return. When we think about Finch Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| James Rolke | Revelation Biosciences | 56 | |
| Gerald Goodman | Nutriband | 77 | |
| Chulani Karunatilake | Werewolf Therapeutics | 65 | |
| Sharon Townson | Monte Rosa Therapeutics | 50 | |
| Gordon JD | Quoin Pharmaceuticals Ltd | 61 | |
| Christopher Frankenfield | Xilio Development | 43 | |
| Nathanael Gray | C4 Therapeutics | N/A | |
| Silvia Buonamici | Monte Rosa Therapeutics | N/A | |
| Kelly Schick | C4 Therapeutics | 45 | |
| Sean Jeffries | Design Therapeutics | 45 | |
| BCPS PharmD | Xilio Development | 47 | |
| Bill Avery | Xilio Development | N/A | |
| Isabel Aznarez | Stoke Therapeutics | 53 | |
| Vicky Hahne | Celcuity LLC | 58 | |
| Ellen MBA | Werewolf Therapeutics | 49 | |
| Evan Hecker | Ikena Oncology | N/A | |
| John Castle | Monte Rosa Therapeutics | 54 | |
| James Ahlers | RenovoRx | 60 | |
| Martin MD | Xilio Development | 63 | |
| Lauren White | C4 Therapeutics | N/A | |
| Badreddin Edris | Edgewise Therapeutics | 38 | |
Management Performance
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.22 |
Finch Therapeutics Leadership Team
Elected by the shareholders, the Finch Therapeutics' board of directors comprises two types of representatives: Finch Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Finch. The board's role is to monitor Finch Therapeutics' management team and ensure that shareholders' interests are well served. Finch Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Finch Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA, Chief Officer | ||
| Lance CPA, Chief Officer | ||
| Bryan MBA, Chief Officer | ||
| Sonia Timberlake, VP Research | ||
| CFA CFA, Principal COO | ||
| Mark Smith, CEO Director | ||
| Alka Batycky, Chief Officer | ||
| JD Esq, Chief Sec | ||
| Matthew JD, Chief Officer | ||
| James Sigler, Ex CMC | ||
| James MBA, Executive CMC |
Finch Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Finch Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.22 | ||||
| Current Valuation | 10.74 M | ||||
| Shares Outstanding | 1.61 M | ||||
| Shares Owned By Insiders | 53.48 % | ||||
| Shares Owned By Institutions | 11.35 % | ||||
| Number Of Shares Shorted | 19.2 K | ||||
| Price To Book | 0.14 X | ||||
| Price To Sales | 30.46 X | ||||
| Revenue | 107 K |
Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Consideration for investing in Finch Pink Sheet
If you are still planning to invest in Finch Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Finch Therapeutics' history and understand the potential risks before investing.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |